Magnetic Seizure Theapy (MagPro XP MST) for Melancholia
This study is evaluating whether magnetic seizure therapy is a feasible treatment for depression in people with Parkinson's disease.
See full descriptionAbout the trial for Melancholia
Treatment Groups
This trial involves 2 different treatments. Magnetic Seizure Theapy (MagPro XP MST) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Magnetic Seizure Theapy (MagPro XP MST) will improve 3 primary outcomes and 1 secondary outcome in patients with Melancholia. Measurement will happen over the course of 18 months.
Who is running the study
Principal InvestigatorPatient Q & A Section
What causes melancholia?
Melancholias are associated with biological abnormalities in the nervous system. Depressed subjects may have a reduced serotonin, noradrenalin, and adrenaline response to emotional stimuli, although their response to other tasks is normal. Some genes for the serotonin transporter, including SLC6A4, may be responsible for some cases of major depression. However, most cases of depression are not associated with a malfunction of genes involved in serotonin metabolism.\n
What is melancholia?
Melancholia is a mental symptom often found on depressive disorders. The characteristic of sadness, gloominess, fatigue, and hopelessness associated with this disorder may be more disabling than the mood symptoms themselves. The prognosis after treatment may be less favorable but long-term prognosis may be better. Therefore, the diagnosis and treatment of melancholia are important.
What are the signs of melancholia?
The most noticeable signs of melancholia include a blunted affect, lethargy, decreased energy, poor concentration and sleep disturbances. Symptoms appear at a later stage of the illness than for those suffering from an anxiety disorder or other types of bipolar disorder. Mood disorders appear to increase at different steps of the illness's duration. Schizophrenia is only one in a spectrum of mood disorders that occur in bipolar-affected bipolar patients. Melancholia is a mood state that occurs very independently of manic-depressive episodes in bipolar disorder, and has been associated with an increased risk of suicide.
How many people get melancholia a year in the United States?
The DSM-IV-TR criteria of clinically substantial depressive episodes were met or exceeded by 6-million Americans in a year and more. As evidenced by the substantial increase in the prevalence of depression for more than 50 years, it is important to increase our understanding of what constitutes clinically significant severity and to increase the level of clinical monitoring and treatment for patients with substantial depressive symptoms.
What are common treatments for melancholia?
Treatment of depression is the treatment of choice for melancholia. The evidence suggests that treatment with antidepressants improves symptoms over four weeks and reduces depressive symptoms or improves functioning at longer follow-up. It is unclear whether or not antidepressants also reduce suicidal thoughts or behavior. In those with more severe depression who are not able to tolerate antidepressant therapy, or have experienced treatment side effects such as increased thoughts of suicide, a mood stabilizer may be useful. The evidence in the published literature is too weak in most cases for this to be a recommendation. There is moderate evidence of benefit for the use of a benzodiazepine, a atypical antipsychotic or lithium in combination with antidepressants in people with severe depression, but more research is needed.
Can melancholia be cured?
For every 3 patients with a history of melancholia, only 1 completes remission. The number of episodes of melancholia correlates with the number of treatments applied. Our conclusion is that it is important to evaluate the patient's history, to obtain data on the time to resolution of symptoms and the number of treatments applied, and to try a different treatment in cases of long-running clinical ineffectiveness.
What does magnetic seizure theapy (magpro xp mst) usually treat?
While this treatment might be suitable for patients with partial epilepsies because of its efficacy in some epileptic patients who have developed resistance to antiepileptic medications, there are several other reasons why it is not suitable for some patients. However, it could be useful in the treatment of refractory status epilepticus and for patients with severe and/or disabling symptoms who wish to get a short-lasting remission.
How does magnetic seizure theapy (magpro xp mst) work?
Results from a recent clinical trial suggest that mST is not just a powerful treatment of epileptic seizures but may influence the pathomechanism(s) underlying the genesis of the spontaneous pain in the postictally depressed phase. These data suggest that mST can be used as an effective treatment for pain-related mood disorders and may be useful in the search for new methods to treat mood disorders and their comorbidities.
What are the common side effects of magnetic seizure theapy (magpro xp mst)?
[Approximately 80% of patients with MST have adverse effects (nausea, diarrhea, insomnia) that are reversible upon withdrawing the therapy. The treatment intensity has to be reduced if patients have gastrointestinal symptoms. The use of magnesium sulfate for prophylaxis should be reconsidered, and the dose of MST should be reduced or even stopped.]{http://www.ncbi.nlm.nih.gov/pubmed/27692876/index.
Who should consider clinical trials for melancholia?
In a recent study, findings shows that patients of different ages who are treated for melancholia may have differing efficacy in responding to clinical trials and that they have distinct characteristics. Clinical trials appear to be effective for patients from all age groups. However, although patients as young as 45 may be considered for clinical trials, only 20% of eligible patients are in such trials.
Is magnetic seizure theapy (magpro xp mst) typically used in combination with any other treatments?
Magnetic seizure therapy is usually used in combination with other treatments when there is a shortage of conventional treatment or a relapse. The authors of this study found that in its most basic formulation, magneto-neurology therapy is usually followed by medication in the field of neuropsychiatry. In particular, antidepressant substances with other indications, such as benzodiazepines, may be administered.\nmagnetic seizure therapy should now be used in combination with medication when conventional therapy fails to control the symptoms. According to the study's results this combination results in the shortest response time and can, therefore, be recommended as an alternative treatment. \nYou can find the most recent epilepsy clinical trials by using [Power](http://www.
Has magnetic seizure theapy (magpro xp mst) proven to be more effective than a placebo?
Magpro (magnetic seizure therapy) led to a significant decrease in depressive symptoms. Magpro is not an effective treatment for depression and it would be best to seek out professional help about treatment. A follow up study of the effect of Magpro on quality of life is therefore needed.